Organization | Rabin Medical Center

Rabin Medical Center Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial

2013

NCT01732250

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

dafna yahav | GALIA AVRAHAMI | Institution of Hematology, Rabin Medical Center | Mical Paul | moshe yeshurun | ori snapiri | Yariv yogev

Active Ingredients

Drugs in Phase 4 Trials (3)

bnt162b2 (1 trial)

colistin (1 trial)

meropenem (merrem) (1 trial)

Drugs in Phase 3 Trials (4)

acetylcysteine (mucomyst) (1 trial)

dexamethasone (1 trial)

hexakaprone (1 trial)

oxytocin (syntocinon) (1 trial)

Drugs in Other Trials (6)

cyclophosphamide (cytoxan) (1 trial)

dacarbazine (dtic-dome) (1 trial)

doxorubicin (Doxil) (1 trial)

etoposide (vepesid) (1 trial)

prednisone (meticorten) (1 trial)

vincristine (oncovin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Bacterial Infections (Phase 4)

Gram-Negative Bacterial Infections (Phase 4)

Hemorrhage (Phase 3)

Postpartum Hemorrhage (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 13